Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

1D-LSD

This article is a stubmissing:
Pharmacology
Tolerance
Harm Potential
History & Culture
1D-LSD molecule structure1D-LSD molecule structure
1-(1,2-Dimethylcyclobutane-1-carbonyl)-lysergic acid diethylamide
SYN-L-229
Psychoactive Class
Chemical Class

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~25 µg
Light25-75 µg
Moderate75-150 µg
Strong150+ µg

1D-LSD functions as a prodrug that is converted to LSD in the body, so dosing guidelines are derived from this metabolic relationship.

Duration

Onset30-60 minutes
Peak4-6 hours
Total10-14 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Increased bodily control

Cognitive

In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, 1D-LSD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.

Visual

Geometry

The visual geometry of 1D-LSD can be described as more similar in appearance to that of 2C-B and the 2C-x family than psilocin, LSA, or DMT. They can be comprehensively described as unstructured in organization, algorithmic and digital in geometric style, intricate in complexity, large in size, fast and smooth in motion, multicoloured in scheme, bright and flat in colour, and sharp in their edges with extremely angular corners. At higher dosages they consistently result in states of Level 7A visual geometry.

Hallucinatory States

1D-LSD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.

External hallucinations

Auditory

Adapted from the LSD subjective effects documentation. 1D-LSD is a prodrug of LSD and is reported to produce an effectively identical experience. Forked from Subjective Effect Documentation byJosie Kins October 2012.

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Ehrlich(EH)
No reaction
No reaction
Powered by PROtestkit.eu

Pharmacology

Pharmacology not written up yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

Powered by TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Harm Potential not written up yet

History & Culture

History & Culture not written up yet

Legality

By Country

Illegal2
Austria flagAustriaIllegal (analog/blanket ban)
Germany flagGermanyIllegal (analog/blanket ban)

References

Source Pages

  1. Bluelight: 1D-LSD Megathread
  2. Ehrlich reagent discussion for 1D-LSD testing (Bluelight)
  3. Erowid Experience: Herald of the Long Unknown (150 ug 1D-LSD)
  4. Erowid Experience: Two Very Different Ego-Losses (1S-LSD & 1D-LSD)
  5. Erowid: 1D-LSD Experience Reports
  6. PsychonautWiki: Subjective Effect Index
  7. Wikipedia

Citations

  1. Draft Regulation on the (17th) amendment of Regulation No. 233/2001 on habit-forming and narcotic substances and other controlled substances, Annex I. technical-regulation-information-system.ec.europa.eu (n.d.). https://technical-regulation-information-system.ec.europa.eu/en/notification/25725/text/D/EN1
  2. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), consolidated text. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007642/NPSV%2c%20Fassung%20vom%2002.09.2026.pdf1
  3. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Anlage II. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261441/II_106_2024_Anlage_II.pdf1
  4. Neue-Psychoaktive-Substanzen-Verordnung (NPSV), Anlage III structural examples. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/Dokumente/Bundesnormen/NOR40261442/II_106_2024_Anlage_III.pdf1
  5. BGBl. II Nr. 106/2024, amendment of the Neue-Psychoaktive-Substanzen-Verordnung. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2024_II_106/BGBLA_2024_II_106.html1
  6. Neue-Psychoaktive-Substanzen-Gesetz (NPSG), consolidated text. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007605/NPSG%2c%20Fassung%20vom%2002.09.2026.pdf1
  7. Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
  8. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 2 Begriffsbestimmungen. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__2.html1
  9. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 3 Unerlaubter Umgang mit neuen psychoaktiven Stoffen. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
  10. Fünfte Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes, BGBl. 2024 I Nr. 210. recht.bund.de (n.d.). https://www.recht.bund.de/bgbl/1/2024/210/regelungstext.pdf?__blob=publicationFile&v=11

Further Reading

  1. Human Psychopharmacology: Comparative study of LSD and LSD analogues
  2. Identification of 1-(thiophene-2-carbonyl)-LSD (1T-LSD) in blotters labelled 1D-LSD
  3. N 1-acyl lysergamide prodrugs – review of abuse potential
  4. N1-acyl lysergamide prodrugs - review of abuse potential
  5. Okada et al. (2024): Synthesis & characterization of 1T-AL-LAD
  6. Reddit r/Drugs: 1D-LSD potency discussion
  7. Reddit r/LSD: 1D-LSD user survey (150 ug vs 225 ug)
  8. Reddit: first-time 1D-LSD report (faster onset, shorter trip)
  9. Sky News: Germany schedules 1D-LSD (June 14, 2024)

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 1D-LSD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.